Welcome to the Discoveries from ASH: Benign Hematology Resource Center. This resource center provides take-home messages from the ASH Annual Meeting and Exposition on the management of benign hematologic conditions, such as hemophilia and thalassemia. Bookmark this page and visit often to hear experts provide context on the major findings presented on the treatment of benign hematologic conditions, including results of the TWiTCH trial, which compared the use of transfusion plus chelation with hydroxyurea plus phlebotomy in children with sickle cell disease at high risk for stroke. In addition, view analyses of the HUSTLE trial, which demonstrated that intensifying hydroxyurea to its maximal tolerated dose in young children with sickle cell anemia provided stable long-term improvements, and the NuProtect study, which demonstrated that the use of a new human-cell derived recombinant Factor VIII resulted in a low rate of inhibitor development among previously untreated patients with severe hemophilia A.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.